Torrent Pharma is back at the negotiating table, trying to buy KKR’s stake in JB Chemicals & Pharmaceuticals. This isn’t the first time they’ve tried—talks stalled earlier—but the renewed interest suggests Torrent is serious about expanding its footprint in the pharma sector. If the deal goes through, it could shake up the competitive landscape.

Editor’s Note: Big pharma deals like this often signal where the industry’s headed—consolidation, bigger players swallowing smaller ones, or companies betting on specific markets. For investors and competitors, it’s worth watching because Torrent gaining a bigger slice of JB Chem could mean shifts in pricing, supply chains, or even which drugs get prioritized. Plus, failed talks before mean there might still be hurdles, so don’t count your pills before they’re bottled.